Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Brokerages

Moderna, Inc. (NASDAQ:MRNAGet Rating) has been given an average rating of “Hold” by the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $246.92.

A number of equities analysts have recently commented on MRNA shares. UBS Group initiated coverage on Moderna in a report on Friday, January 21st. They issued a “neutral” rating and a $221.00 target price for the company. Jefferies Financial Group dropped their price objective on shares of Moderna from $200.00 to $170.00 in a research note on Friday, February 25th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Moderna from $175.00 to $155.00 and set a “hold” rating on the stock in a research note on Monday, March 7th. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $135.00 to $180.00 in a research note on Friday, January 21st. Finally, Redburn Partners raised shares of Moderna from a “sell” rating to a “neutral” rating in a research report on Tuesday, February 1st.

In other news, insider Juan Andres sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 9th. The stock was sold at an average price of $154.26, for a total value of $308,520.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Stephen Hoge sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $141.93, for a total value of $1,419,300.00. Following the completion of the sale, the president now owns 1,622,532 shares in the company, valued at approximately $230,285,966.76. The disclosure for this sale can be found here. Insiders have sold a total of 201,054 shares of company stock worth $31,961,144 in the last 90 days. 17.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Glassman Wealth Services lifted its holdings in shares of Moderna by 13.6% in the 3rd quarter. Glassman Wealth Services now owns 360 shares of the company’s stock valued at $139,000 after buying an additional 43 shares during the period. Jacobi Capital Management LLC increased its holdings in shares of Moderna by 9.9% during the 3rd quarter. Jacobi Capital Management LLC now owns 501 shares of the company’s stock valued at $193,000 after purchasing an additional 45 shares in the last quarter. D Orazio & Associates Inc. lifted its stake in shares of Moderna by 15.7% in the 3rd quarter. D Orazio & Associates Inc. now owns 347 shares of the company’s stock valued at $134,000 after purchasing an additional 47 shares during the period. RB Capital Management LLC boosted its holdings in Moderna by 2.5% during the third quarter. RB Capital Management LLC now owns 1,965 shares of the company’s stock worth $756,000 after buying an additional 47 shares in the last quarter. Finally, Piscataqua Savings Bank grew its position in Moderna by 18.2% during the fourth quarter. Piscataqua Savings Bank now owns 325 shares of the company’s stock valued at $83,000 after buying an additional 50 shares during the period. 61.20% of the stock is currently owned by institutional investors.

NASDAQ MRNA opened at $134.40 on Friday. Moderna has a one year low of $122.01 and a one year high of $497.49. The company has a market capitalization of $54.17 billion, a P/E ratio of 3.95, a P/E/G ratio of 0.88 and a beta of 1.70. The stock has a 50 day moving average price of $156.32 and a 200-day moving average price of $207.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.60 and a current ratio of 1.77.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $2.42. The firm had revenue of $6.07 billion during the quarter, compared to the consensus estimate of $4.43 billion. Moderna had a net margin of 64.77% and a return on equity of 121.86%. The firm’s revenue for the quarter was up 213.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 EPS. As a group, equities analysts predict that Moderna will post 27.06 EPS for the current fiscal year.

Moderna Company Profile (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

See Also

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.